1. Home
  2. Companies
  3. LTP
  4. Material Events

Ltr Pharma (ASX:LTP) — Material Events

ASX:LTP · 19 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 17 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
17
LTR Pharma Hits 1,000 SPONTAN Prescriptions, Eyes US Launch in H1 2026Medium
LTR Pharma advances clinical trials and US launch plans with strong cash position
28 Jan 2026 ·Quarterly Activities Report & Appendix 4C ·85
LTR Pharma Advances US Launch with SPONTAN Phase II Data and ROXUS AgreementsMedium
LTR Pharma advances clinical and commercial milestones with SPONTAN Phase II data and US ROXUS launch agreements
28 July 2026 ·Quarterly Activities Report and Appendix 4C ·85
LTR Pharma Secures Definitive US Deal with Shed to Launch ROXUS Intranasal ED TreatmentMedium
LTR Pharma signs definitive U.S. commercial agreement with Shed for ROXUS® launch
17 July 2026 ·Commercial Agreement ·85
LTR Pharma Locks in US Telehealth Deal with 150,000-Unit ROXUS TargetMedium
LTR Pharma signs binding U.S. telehealth deal with Shed Holdings for ROXUS commercialisation
9 June 2026 ·Commercialisation Agreement ·85
LTR Pharma Advances US Market Entry with ROXUS Deals and SPONTAN Phase II ProgressMedium
LTR Pharma advances intranasal ED therapies with US commercial deals and clinical progress, reports FY26 loss of A$14.16 million
28 Aug 2026 ·Annual Report ·85
LTR Pharma’s SPONTAN Shows Strong Real-World Response in Post-Prostatectomy and Convenience-Seeking MenMedium
LTR Pharma's SPONTAN shows 93% response in convenience-seeking men and 64% in post-prostatectomy patients
11 Aug 2026 ·Clinical Study Results ·85
LTR Pharma Advances Rapid-Onset Intranasal ED Therapy SPONTAN with Strong Clinical DataMedium
LTR Pharma advances rapid-onset intranasal ED therapy SPONTAN with strong clinical data, strategic partnerships, and $24.1M cash
1 May 2026 ·Investor Update ·85
LTR Pharma Accelerates US Launch with New Advisory Board and Clinical ValidationMedium
LTR Pharma advances ROXUS US launch, strengthens advisory board, and expands omega-3 portfolio with strong cash position
29 Oct 2025 ·Quarterly Activities Report & Appendix 4C ·85
LTR Pharma Secures Definitive US Manufacturing Deal for ROXUS LaunchMedium
LTR Pharma finalizes U.S. commercial agreement with Strive Pharmacy for ROXUS® launch
20 July 2026 ·Commercial Agreement ·80
LTR Pharma Secures Exclusive US Pharmacy Partner to Boost ROXUS LaunchMedium
LTR Pharma secures exclusive US pharmacy partner for ROXUS® ahead of commercial launch
11 June 2026 ·Partnership Agreement Announcement ·80
LTR Pharma’s OROFLOW® Gains Ethics Nod to Target $8 Billion Oesophageal Motility MarketMedium
LTR Pharma's OROFLOW® Intranasal Spray Approved for Clinical Study in Oesophageal Motility Disorders
24 June 2026 ·Clinical Study Announcement ·75
LTR Pharma Advances SPONTAN Trial with Ethics Nod for Older Men StudyMedium
LTR Pharma secures ethics approval for SPONTAN Phase II clinical trial targeting older men
3 Dec 2025 ·Clinical Trial Announcement ·75
LTR Pharma Completes Phase II Recruitment for SPONTAN, Data Due Q2 2026Medium
LTR Pharma completes Phase II recruitment for SPONTAN ED treatment, data expected Q2 2026
5 Mar 2026 ·Clinical Trial Update ·75
LTR Pharma Secures 33% Stake in LevOmega to Tap Into Pharma-Grade Omega-3 MarketMedium
LTR Pharma acquires 33% stake in LevOmega to enter pharmaceutical-grade omega-3 market
22 Sept 2025 ·Equity Investment Announcement ·75
LTR Pharma Doses First Patients in Pivotal SPONTAN Phase II StudyMedium
LTR Pharma initiates Phase II dosing for SPONTAN erectile dysfunction spray
22 Jan 2026 ·Clinical Trial Update ·75
LTR Pharma Completes SPONTAN Phase II Recruitment; Interim Data Due Q2 2026Medium
LTR Pharma completes SPONTAN Phase II recruitment; interim data due Q2 2026; ROXUS US commercial talks progress
28 Apr 2026 ·Quarterly Activities Report & Appendix 4C ·75
LTR Pharma Affirms Timely Disclosure of US ROXUS Deal Amid ASX Trading InquiryMedium
LTR Pharma confirms timely disclosure of binding US ROXUS agreement following ASX query
15 June 2026 ·ASX Query Response ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.